SARS-CoV-2 Recombinant Spike Protein-based Vaccine: A Promising Candidate against the Recent Imperial Coronavirus Disease (COVID-19)

References (117)

1. 1 Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus [DOI]
2. 2 Coronaviruses: An Overview of Their Replication and Pathogenesis [DOI]
3. 3 A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury [DOI]
4. 4 Bats Are Natural Reservoirs of SARS-Like Coronaviruses [DOI]
5. 5 Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC [DOI]
6. 6 Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor [DOI]
7. 7 The Molecular Biology of Coronaviruses [DOI]
8. 8 Coronaviruses post-SARS: update on replication and pathogenesis [DOI]
9. 9 The spike protein of SARS-CoV — a target for vaccine and therapeutic development [DOI]
10. 10 Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein [DOI]
11. 11 Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways [DOI]
12. 12 SARS-Coronavirus Replication Is Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum [DOI]
13. 13 Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus [DOI]
14. 14 Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans [DOI]
15. 15 Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5 [DOI]
16. 16 A decade after SARS: strategies for controlling emerging coronaviruses [DOI]
17. 17 Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex [DOI]
18. 18 Molecular Interactions in the Assembly of Coronaviruses [DOI]
19. 19 A Strategy To Estimate Unknown Viral Diversity in Mammals [DOI]
20. 20 The mercurial nature of neutrophils: still an enigma in ARDS? [DOI]
21. 21 A review of studies on animal reservoirs of the SARS coronavirus [DOI]
22. 22 Human immunopathogenesis of severe acute respiratory syndrome (SARS) [DOI]
23. 23 Human Betacoronavirus 2c EMC/2012–related Viruses in Bats, Ghana and Europe [DOI]
24. 24 Ready, Set, Fuse! The Coronavirus Spike Protein and Acquisition of Fusion Competence [DOI]
25. 25 Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step [DOI]
26. 26 Comparative Analysis of Twelve Genomes of Three Novel Group 2c and Group 2d Coronaviruses Reveals Unique Group and Subgroup Features [DOI]
27. 27 Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody [DOI]
28. 28 Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies [DOI]
29. 29 Antibodies to SARS Coronavirus in Civets [DOI]
30. 30 Coronaviruses: Important Emerging Human Pathogens [DOI]
31. 31 Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model [DOI]
32. 32 Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection [DOI]
33. 33 SARS coronavirus replicase proteins in pathogenesis [DOI]
34. 34 Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice [DOI]
35. 35 A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines [DOI]
36. 36 Full-Genome Deep Sequencing and Phylogenetic Analysis of Novel Human Betacoronavirus [DOI]
37. 37 Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome [DOI]
38. 38 Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity [DOI]
39. 39 Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate [DOI]
40. 40 A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice [DOI]
41. 41 Avian influenza A H5N1 virus: a continuous threat to humans [DOI]
42. 42 SARS-like virus in the Middle East: A truly bat-related coronavirus causing human diseases [DOI]
43. 43 Coronavirus transcription: subgenomic mouse hepatitis virus replicative intermediates function in RNA synthesis [DOI]
44. 44 Severe acute respiratory syndrome (SARS) S protein production in plants: Development of recombinant vaccine [DOI]
45. 45 Host Responses from Innate to Adaptive Immunity after Vaccination: Molecular and Cellular Events [DOI]
46. 46 Human Coronaviruses 229E and NL63: Close Yet Still So Far [DOI]
47. 47 Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells [DOI]
48. 48 Development of subunit vaccines against severe acute respiratory syndrome [DOI]
49. 49 The N-Terminal Domain of the Murine Coronavirus Spike Glycoprotein Determines the CEACAM1 Receptor Specificity of the Virus Strain [DOI]
50. 50 Middle East respiratory syndrome: current status and future prospects for vaccine development [DOI]
51. 51 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
52. 52 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
53. 53 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
54. 54 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [DOI]
55. 55 Pathological findings of COVID-19 associated with acute respiratory distress syndrome [DOI]
56. 56 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
57. 57 Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus [DOI]
58. 58 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses [DOI]
59. 59 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [DOI]
60. 60 Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology [DOI]
61. 61 Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China [DOI]
62. 62 Coronaviruses — drug discovery and therapeutic options [DOI]
63. 63 Molecular immune pathogenesis and diagnosis of COVID-19 [DOI]
64. 64 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [DOI]
65. 65 Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003 [DOI]
66. 66 Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats [DOI]
67. 67 Multiple organ infection and the pathogenesis of SARS [DOI]
68. 68 From SARS to MERS, Thrusting Coronaviruses into the Spotlight [DOI]
69. 69 Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection [DOI]
70. 70 COVID-19: combining antiviral and anti-inflammatory treatments [DOI]
71. 71 Zoonotic origins of human coronaviruses [DOI]
72. 72 Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia [DOI]
73. 73 Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission [DOI]
74. 74 Molecular Evolution of Human Coronavirus Genomes [DOI]
75. 75 Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants [DOI]
76. 76 IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes [DOI]
77. 77 The SARS-CoV-2 Vaccine Pipeline: an Overview [DOI]
78. 78 GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses [DOI]
79. 79 A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option [DOI]
80. 80 Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy [DOI]
81. 81 Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses [DOI]
82. 82 Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report [DOI]
83. 83 Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion [DOI]
84. 84 Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants [DOI]
85. 85 Evolutionary History of the Closely Related Group 2 Coronaviruses: Porcine Hemagglutinating Encephalomyelitis Virus, Bovine Coronavirus, and Human Coronavirus OC43 [DOI]
86. 86 Evidence for an Ancestral Association of Human Coronavirus 229E with Bats [DOI]
87. 87 Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects [DOI]
88. 88 New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections [DOI]
89. 89 Link of a ubiquitous human coronavirus to dromedary camels [DOI]
90. 90 Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants [DOI]
91. 91 Jumping species—a mechanism for coronavirus persistence and survival [DOI]
92. 92 Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate [DOI]
93. 93 Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment [DOI]
94. 94 Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters [DOI]
95. 95 Antibodies and vaccines against Middle East respiratory syndrome coronavirus [DOI]
96. 96 Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients [DOI]
97. 97 Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection [DOI]
98. 98 Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases [DOI]
99. 99 A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV [DOI]
100. 100 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody [DOI]
101. 101 Home visits: a strategy to improve newborn survival - Authors' reply [DOI]
102. 102 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV [DOI]
103. 103 The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 [DOI]
104. 104 Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma [DOI]
105. 105 Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System [DOI]
106. 106 COVID-19: immunopathology and its implications for therapy [DOI]
107. 107 A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV [DOI]
108. 108 Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein [DOI]
109. 109 SARS-CoV-2 Vaccines: Status Report [DOI]
110. 110 Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses [DOI]
111. 111 SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes [DOI]
112. 112 Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets [DOI]
113. 113 SARS-CoV-2: Camazotz's Curse [DOI]
114. 114 Avian Influenza (H5N1) Infection in Humans [DOI]
115. 115 Coronavirus immunogens [DOI]
116. 116 Subgenomic Negative-Strand RNA Function during Mouse Hepatitis Virus Infection [DOI]
117. 117 Research and development on therapeutic agents and vaccines for covid-19 and related human coronavirus diseases [DOI]

Cited by 7

Showing 4 of 7 known citations — external sources report more than can currently be individually listed.

Related research

• Covid-2019:“A Microbiological Monster” — shares topic coverage
• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Using Ultraviolet A to Check Inanimate Objects for Thorough Cleanliness during COVID-19 Pandemic — shares topic coverage
• The Evaluation of Biochemical Parameters in Positive COVID-19 RealTime PCR Patients: A Retrospective Study — shares topic coverage
• Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19) — shares topic coverage